MBRX (Moleculin Biotech) Buyback Yield %: -171.71 (As of Jul. 02, 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $2.69
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Buyback Yield %?

Moleculin Biotech MBRX -2.89% 30 Buyback Yield % is -171.71 as of Jul. 02, 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 745 Biotechnology companies, Moleculin Biotech ranks worse than 92.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Moleculin Biotech's current buyback yield was -171.71%.

Moleculin Biotech Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Buyback Yield % Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,522.17 0.00 -363.54 -2,030.50 -243.33

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.14 -147.10 -71.19 -243.33 -207.72

MBRX vs JAGX, BCDA, AKTX: Buyback Yield % Comparison

For the Biotechnology subindustry, Moleculin Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moleculin Biotech Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Buyback Yield % falls into.


MBRX
30GF Score
Moleculin Biotech Inc MBRX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Moleculin Biotech's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 25.765) / 10.58869
=-243.33%

Moleculin Biotech's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 25.382) / 12.21944
=-207.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -171.71 mean?
Moleculin Biotech (MBRX) has a Buyback Yield % of -171.71 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #691 out of 745 companies in the Biotechnology industry, placing it in the top 92.8%.
Is Moleculin Biotech's Buyback Yield % too high?
Moleculin Biotech's current Buyback Yield % is -171.71. Based on the distribution chart, Moleculin Biotech ranks #691 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Buyback Yield % compare to JAGX and BCDA?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #691 out of 745 companies for Buyback Yield %. This places Moleculin Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Buyback Yield % is -171.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Buyback Yield % of -171.71. The current Buyback Yield % is -171.71. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Buyback Yield % is -171.71 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price